Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Net Margin (2016 - 2025)

Plus Therapeutics has reported Net Margin over the past 13 years, most recently at 417.92% for Q4 2025.

  • Quarterly Net Margin fell 14151.0% to 417.92% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 301.75% through Dec 2025, down 5104.0% year-over-year, with the annual reading at 301.75% for FY2025, 5104.0% down from the prior year.
  • Net Margin was 417.92% for Q4 2025 at Plus Therapeutics, down from 316.61% in the prior quarter.
  • Over five years, Net Margin peaked at 73.16% in Q3 2023 and troughed at 7186.3% in Q3 2022.
  • The 4-year median for Net Margin is 288.05% (2023), against an average of 1088.07%.
  • Year-over-year, Net Margin skyrocketed 711314bps in 2023 and then crashed -20793bps in 2024.
  • A 4-year view of Net Margin shows it stood at 4417.32% in 2022, then surged by 93bps to 290.18% in 2023, then grew by 5bps to 276.42% in 2024, then plummeted by -51bps to 417.92% in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Net Margin are 417.92% (Q4 2025), 316.61% (Q3 2025), and 108.71% (Q2 2025).